On Jun. 29, 2020, LabCorpﾮ announced that Covance, its drug development business, has deployed the Xcellerateﾮ COVID-19 solution as part of its Xcellerate platform. Covance has developed a comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery.

Designed in conjunction with Covanceﾒs COVID-19 Operational Recovery Team, the Xcellerateﾮ COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.